CJC-1295
- Category
- Growth Hormone
- Administration routes
- Injectable
- Regulatory status
- Not FDA-approved
What it is
A synthetic growth hormone-releasing hormone analog, often built with a Drug Affinity Complex (DAC) that extends its half-life to days, marketed for body composition, sleep, recovery, and bone. It reliably raises growth hormone, but the clinical benefits remain speculative in humans. Safety is the gap: long-term data is thin, the long-acting form is hard to stop, and it can cause water retention and joint pain. Not an approved US drug and banned by WADA.
Read Full recordStudied uses & evidence
Studied uses(7)
Sustained GH elevation
HighHuman RCT showed GH rising 2 to 10x for 6+ days per injection, accumulating with repeat dosing.
Preserved GH pulsatility
MediumHuman trial data indicate the natural GH pulse pattern is maintained, unlike exogenous GH.
Improved body composition
SpeculativePreliminary, based on the GH/IGF-1 rise promoting lipolysis and lean mass; no completed outcome trial.
Evidence limits
- Evidence Level
- Phase 2 (Discontinued)
Foundational 2006 Teichman et al. RCT demonstrated dose-dependent GH/IGF-1 elevation. Ionescu 2006 confirmed preserved pulsatility. Development halted after Phase II death (attributed to pre-existing CAD). No further pharma-sponsored trials.
Benefits = confidence in the evidence: High · Medium · Low · Speculative (High requires human randomized trials for that specific benefit)
Cautions & risk summary
Do not use if
Pituitary tumors
AbsoluteDirectly stimulates pituitary GHRH receptors.
Active cancer
HighSustained GH elevation via GHRH mimicry may promote tumor growth.
Diabetic retinopathy
HighGH/IGF-1 axis activation can accelerate retinal damage.
General cautions
Pregnancy
AbsoluteNo safety data.
Risk summary(6)
Risks = level of concern: High · Moderate · Low · Theoretical
One Phase II death was reported; coronary artery disease was considered the likely explanation, with drug causality unresolved.
LowLong-term safety data beyond a few months is lacking
HighDAC version half-life 6-8 days cannot quickly discontinue if adverse reaction
ModerateWater retention (hands, feet, face)
ModeratePotential GH-related side effects: joint pain, carpal tunnel, insulin resistance
ModerateWADA banned
High
Further reading
- Overview in Full record
- Safety & interactions in Full record
- Research & benefits in Full record
- Regulation & availability in Full record
- Sources in Full record
- Frequently asked questions in Full record
This is educational content compiled from published research, not medical advice. Always consult a licensed healthcare provider before using any peptide. Medical disclaimer
Compiled from published research indexed through March 2026.